Publications by authors named "Moral-Leal M"
Innovation ecosystems foster collaboration between academia, industry, public bodies, and civil society to drive technological and social advancements. The European Innovation Partnership on Active and Healthy Aging (EIP on AHA), launched in 2012, aimed to extend healthy life years, improve healthcare efficiency, and stimulate economic growth. Reference sites (RSs) and action groups (AGs) were key components, with RSs adopting collaborative approaches to improve health outcomes.
View Article and Find Full Text PDFArticle Synopsis
- Tamoxifen (TMX) is a drug used to treat breast cancer and is banned by the World Anti-Doping Agency due to its potential performance-enhancing effects.
- The study utilized ultra-high-performance liquid chromatography electrospray time-of-flight mass spectrometry (UHPLC-TOFMS) to analyze the urinary metabolites of TMX in rats after a single therapeutic dose, employing a solid-phase extraction method for urine samples.
- A total of 38 TMX metabolites were detected, including new metabolites not previously reported, highlighting the effectiveness of the UHPLC-TOFMS approach in metabolite identification.
Detection of main urinary metabolites of β2-agonists clenbuterol, salbutamol and terbutaline by liquid chromatography high resolution mass spectrometry.
J Chromatogr B Analyt Technol Biomed Life Sci
April 2013
Article Synopsis
- Clenbuterol, terbutaline, and salbutamol are banned B2-agonist drugs according to the World Anti-Doping Agency (WADA) and are prohibited in competitions.
- The study examined how these drugs are metabolized and excreted in urine after a single therapeutic dose given to rats, using advanced techniques like liquid chromatography and mass spectrometry.
- The researchers successfully identified 11 metabolites of these drugs, including four novel ones that had not been previously reported in urine, enhancing the understanding of their biological effects and excretion profiles.
Article Synopsis
- The article discusses a new automated approach to systematically identify drug metabolites in urine using advanced mass spectrometry techniques.
- It combines two data mining tools to extract and analyze diagnostic ions and track biotransformations of various sport drugs after administration to rats.
- The method showed promising results, identifying several new metabolites for propranolol and improving the accuracy of metabolite detection while reducing false positives.
Introduction: One of the different molecules involved in the development of astrocytomas is nitric oxide (NO), a gaseous radical that, depending on the cell type and the experimental paradigm selected in the pathology, can play either a cytotoxic or a cytoprotective role.
Development: During the development of an astrocytoma NO acts as a tumouricidal agent, although it can also alter vascular reactivity and lead to neovascularisation, thereby contributing to the invasive capacity (aggressiveness) of the tumour. One of the mechanisms of tumoural progression consists in the protein inactivation resulting from the NO nitration of tyrosine from proteins coded for by tumour-suppressing genes, such as p53.